tradingkey.logo
tradingkey.logo
Search

Windward Bio Announces $165M Crossover Financing To Advance Pipeline Of Long-Acting Immunology Therapies With Best-In-Disease Potential

ReutersMay 4, 2026 11:34 AM
facebooktwitterlinkedin
View all comments0

-

  • WINDWARD BIO ANNOUNCES $165M CROSSOVER FINANCING TO ADVANCE PIPELINE OF LONG-ACTING IMMUNOLOGY THERAPIES WITH BEST-IN-DISEASE POTENTIAL

  • WINDWARD BIO: FINANCING LED BY ORBIMED, RA CAPITAL MANAGEMENT, JANUS HENDERSON INVESTORS, SANOFI VENTURES, HARBOUR BIOMED, EXISTING INVESTORS

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI